Dr John Logue, Consultant Clinical Oncologist
Dr John Logue
Consultant Clinical Oncologist
Dr John Logue MB MRCP FRCR
Consultant Clinical Oncologist
Areas of expertise
- Prostate cancer
- Urological oncology
- Brachytherapy
- Image guided radiotherapy (IGRT)
- Intensity modulated radiotherapy (IMRT)
About Dr John Logue
GMC number: 2554879
Year qualified: 1981
Place of primary qualification: University of Glasgow
Areas of expertise
- Clinical oncology
- Urological oncology
Professional memberships
Articles by Dr John Logue
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 chhip trial
Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial
Updated analysis of the phase iii, double- blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (crpc) patients with bone metastases (alsympca)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 chhip trial
Outcome and patient-reported toxicity in localised prostate cancer treated with dose-escalated hypofractionated intensity-modulated radiotherapy
Dose-escalated hypofractionated intensity-modulated radiotherapy in high-risk carcinoma of the prostate: outcome and late toxicity
Pd-0178: parameterised rectal dose and associations with latetoxicity in high-dose-rate prostate brachytherapy
Ep-1223: endorectal balloons in prostate cancer radiotherapy: effects on seminal vesicle positioning